These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 21596683)

  • 41. In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies.
    Krause KM; Barriere SL; Kitt MM; Benton BM
    Diagn Microbiol Infect Dis; 2010 Oct; 68(2):181-5. PubMed ID: 20846593
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Scenario 1: a patient with hospital-acquired bacterial pneumonia--introduction to clinical trial design issues.
    Gilbert DN
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S10-1. PubMed ID: 20597655
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type.
    Yamamoto M; Kuzuya T; Baba H; Yamada K; Nabeshima T
    J Clin Pharm Ther; 2009 Aug; 34(4):473-83. PubMed ID: 19583681
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Phase II Randomized, Double-blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-positive Pathogens.
    Huang DB; File TM; Torres A; Shorr AF; Wilcox MH; Hadvary P; Dryden M; Corey GR
    Clin Ther; 2017 Aug; 39(8):1706-1718. PubMed ID: 28756068
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multidrug-resistant Enterococcus faecium. An untreatable nosocomial pathogen.
    Spera RV; Farber BF
    Drugs; 1994 Nov; 48(5):678-88. PubMed ID: 7530626
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Recommendations for the treatment of nosocomial infections caused by Gram-positive microorganisms].
    Azanza JR; Barberán J; García-Rodríguez JA; Llinares P; Mensa J; Picazo J; Prieto J; Torre Cisneros J
    Rev Esp Quimioter; 2004 Sep; 17(3):271-88. PubMed ID: 15619658
    [No Abstract]   [Full Text] [Related]  

  • 47. Multiply-resistant Enterococcus faecium. The nosocomial pathogen of the 1990s.
    Spera RV; Farber BF
    JAMA; 1992 Nov; 268(18):2563-4. PubMed ID: 1308665
    [No Abstract]   [Full Text] [Related]  

  • 48. Which antibiotic for hospital acquired pneumonia caused by MRSA?
    Muscedere J
    BMJ; 2014 Feb; 348():g1469. PubMed ID: 24525051
    [No Abstract]   [Full Text] [Related]  

  • 49. Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.
    Van Bambeke F
    Drugs; 2015 Dec; 75(18):2073-95. PubMed ID: 26603874
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria.
    Eliopoulos GM
    J Infect; 2009 Sep; 59 Suppl 1():S17-24. PubMed ID: 19766885
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Workshop on clinical trials of antibacterial agents for hospital-acquired pneumonia and ventilator-associated pneumonia.
    Bartlett JG; Barie PS; Niederman MS; Wunderink RG
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S1-3. PubMed ID: 20597654
    [No Abstract]   [Full Text] [Related]  

  • 52. [Vancomycin resistant Enterococci (VRE)].
    Lesens O
    Nephrol Ther; 2009 Jun; 5 Suppl 4():S261-4. PubMed ID: 19596346
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin.
    Kollef MH; Rello J; Cammarata SK; Croos-Dabrera RV; Wunderink RG
    Intensive Care Med; 2004 Mar; 30(3):388-94. PubMed ID: 14714107
    [TBL] [Abstract][Full Text] [Related]  

  • 54. For nosocomial vancomycin-resistant enterococcal infections: the ounce of prevention or the pound of cure?
    Farr BM
    Clin Infect Dis; 2004 Apr; 38(8):1116-8. PubMed ID: 15095216
    [No Abstract]   [Full Text] [Related]  

  • 55. Nosocomial pneumonia: importance of recognition of aetiological agents to define an appropriate initial empirical therapy.
    Costa SF; Newbaer M; Santos CR; Basso M; Soares I; Levin AS
    Int J Antimicrob Agents; 2001 Feb; 17(2):147-50. PubMed ID: 11165120
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Review of meta-analyses of vancomycin compared with new treatments for Gram-positive skin and soft-tissue infections: Are we any clearer?
    Tsoulas C; Nathwani D
    Int J Antimicrob Agents; 2015 Jul; 46(1):1-7. PubMed ID: 25982913
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A position paper on the treatment of hospital acquired pneumonia (HAP): do we need guidelines?
    Ramphal R
    Acta Clin Belg; 2002; 57(4):202-6. PubMed ID: 12462796
    [No Abstract]   [Full Text] [Related]  

  • 58. Hospital-acquired pneumonia: recent advances in diagnosis, microbiology and treatment.
    Bruchhaus JD; McEachern R; Campbell GD
    Curr Opin Pulm Med; 1998 May; 4(3):180-4. PubMed ID: 9675521
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ceftobiprole for the treatment of pneumonia: a European perspective.
    Liapikou A; Cillóniz C; Torres A
    Drug Des Devel Ther; 2015; 9():4565-72. PubMed ID: 26316697
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.
    Cepeda JA; Whitehouse T; Cooper B; Hails J; Jones K; Kwaku F; Taylor L; Hayman S; Shaw S; Kibbler C; Shulman R; Singer M; Wilson AP
    J Antimicrob Chemother; 2004 Feb; 53(2):345-55. PubMed ID: 14711840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.